Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine-type beta-lactamases are bacterial enzymes that confer resistance to beta-lactam antibiotics (such as penicillins and cephalosporins) by hydrolyzing the characteristic beta-lactam ring of these drugs, rendering them inactive. These enzymes utilize a serine residue in their active site as a nucleophile for catalysis, distinguishing them from metallo-beta-lactamases, which require metal ions. They are classified into Ambler classes A, C, and D based on sequence similarity and structural features. By breaking down β-lactams before they can inhibit cell wall synthesis enzymes (PBPs), these enzymes provide bacteria with robust resistance against many frontline antibiotics. Inhibition strategies focus on molecules that covalently modify key active-site residues or target structurally conserved regions.
Acylation–deacylation using nucleophilic active-site serine
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine-type beta-lactamase enzyme (None).